When manufacturing CAR T therapeutics, scientists typically isolate rare T cell populations from complex mixtures to increase the therapeutic potential, avoid variable clinical outcomes, and enhance treatment safety. However, obtaining well defined T cell subsets is currently a challenge. A fully GMP-ready closed cell sorting system facilitates rare cell isolation and helps develop more potent CAR T therapy.
Download this application note from Sony to learn how a closed cell sorting system efficiently isolates CD4+ naïve T cells within an existing CAR T therapeutics manufacturing process.
